| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories, Okubo 3, Tsukuba 300-33, Japan
NB-506 [6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(ß-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione] is a new antitumor indolocarbazole compound. The growths of murine M5076 and Ehrlich solid tumors were inhibited 76 and 96%, respectively, by i.v. injection at doses of 300 mg/m2. Furthermore, NB-506 caused regression of nodules of human PC-13 lung cancer and MKN-45 stomach cancer cells at i.v. doses of 90 mg/m2. Human HCT 116 and LS 180 colon cancers also regressed with injections of NB-506. Repeated injections of NB-506 had a stronger antitumor effect than intermittent injections in mice with MKN-45. The cumulative toxicity of NB-506 was low in terms of lethality in mice, i.e., the LD50s on single and 10 repeated i.v. injections into CDF1 mice were 990 and 810 mg/m2/injection, respectively. In conclusion, NB-506 is considered to be an interesting possible candidate as an anticancer drug for treatment of solid tumors in humans.
1 To whom requests for reprints should be addressed.
Received 10/18/94. Accepted 1/16/95.
This article has been cited by other articles:
|
|
 |
|
  M. Facompre, C. Carrasco, P. Colson, C. Houssier, J. D. Chisholm, D. L. Van Vranken, and C. Bailly DNA Binding and Topoisomerase I Poisoning Activities of Novel Disaccharide Indolocarbazoles Mol. Pharmacol., November 1, 2002; 62(5): 1215 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Takenaga, M. Ishii, T. Kamei, and T. Yasumori Structure-Activity Relationship in O-Glucuronidation of Indolocarbazole Analogs Drug Metab. Dispos., May 1, 2002; 30(5): 494 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Pilch, E. Allemand, M. Facompre, C. Bailly, J.-F. Riou, J. Soret, and J. Tazi Specific Inhibition of Serine- and Arginine-rich Splicing Factors Phosphorylation, Spliceosome Assembly, and Splicing by the Antitumor Drug NB-506 Cancer Res., September 1, 2001; 61(18): 6876 - 6884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yoshinari, M. Ohkubo, K. Fukasawa, S.-i. Egashira, Y. Hara, M. Matsumoto, K. Nakai, H. Arakawa, H. Morishima, and S. Nishimura Mode of Action of a New Indolocarbazole Anticancer Agent, J-107088, Targeting Topoisomerase I Cancer Res., September 1, 1999; 59(17): 4271 - 4275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Pollack, L. Young, J. Bilsland, N. Wilkie, S. Ellis, F. Hefti, H. Broughton, and S. Harper The Staurosporine-Like Compound L-753,000 (NB-506) Potentiates the Neurotrophic Effects of Neurotrophin-3 by Acting Selectively at the TrkA Receptor Mol. Pharmacol., July 1, 1999; 56(1): 185 - 195. [Abstract] [Full Text]
|
|
|
|
|
|
H. Komatani, M. Morita, N. Sakaizumi, K. Fukasawa, E. Yoshida, A. Okura, T. Yoshinari, and S. Nishimura A New Mechanism of Acquisition of Drug Resistance by Partial Duplication of Topoisomerase I Cancer Res., June 1, 1999; 59(11): 2701 - 2708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bailly, L. Dassonneville, P. Colson, C. Houssier, K. Fukasawa, S. Nishimura, and T. Yoshinari Intercalation into DNA Is Not Required for Inhibition of Topoisomerase I by Indolocarbazole Antitumor Agents Cancer Res., June 1, 1999; 59(12): 2853 - 2860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Takenaga, M. Ishii, S. Nakajima, T. Hasegawa, R. Iwasa, H. Ishizaki, and T. Kamei In Vivo Metabolism of a New Anticancer Agent, 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(beta -D-glucopyranosil)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in Rats and Dogs: Pharmacokinetics, Isolation, Identification, and Quantification of Metabolites Drug Metab. Dispos., February 1, 1999; 27(2): 205 - 212. [Abstract] [Full Text]
|
|
|
|
|
|
N. Takenaga, T. Hasegawa, M. Ishii, H. Ishizaki, S. Hata, and T. Kamei In Vitro Metabolism of a New Anticancer Agent, 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(beta -D-glucopyranosil)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506), in Mice, Rats, Dogs, and Humans Drug Metab. Dispos., February 1, 1999; 27(2): 213 - 220. [Abstract] [Full Text]
|
|
|
|
|
|
C. Bailly, X. Qu, F. Anizon, M. Prudhomme, J.-F. Riou, and J. B. Chaires Enhanced Binding to DNA and Topoisomerase I Inhibition by an Analog of the Antitumor Antibiotic Rebeccamycin Containing an Amino Sugar Residue Mol. Pharmacol., February 1, 1999; 55(2): 377 - 385. [Abstract] [Full Text]
|
|
|
|
|
|
E. Labourier, J.-F. Riou, M. Prudhomme, C. Carrasco, C. Bailly, and J. Tazi Poisoning of Topoisomerase I by an Antitumor Indolocarbazole Drug: Stabilization of Topoisomerase I-DNA Covalent Complexes and Specific Inhibition of the Protein Kinase Activity Cancer Res., January 1, 1999; 59(1): 52 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bailly, P. Colson, C. Houssier, E. Rodrigues-Pereira, M. Prudhomme, and M. J. Waring Recognition of Specific Sequences in DNA by a Topoisomerase I Inhibitor Derived from the Antitumor Drug Rebeccamycin Mol. Pharmacol., January 1, 1998; 53(1): 77 - 87. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
